Interleukin (IL)-17A Inhibitor as a Treatment for Darier Disease in the Pediatric Population

TL;DR

An IL-17A inhibitor improved symptoms and quality of life in a pediatric patient with Darier disease who did not respond to other treatments.

Contribution

This is the first reported case demonstrating the efficacy of IL-17A inhibitors in a pediatric patient with Darier disease.

Findings

A 16-year-old patient showed significant improvement in skin lesions after IL-17A inhibitor treatment.

The treatment improved the patient's quality of life despite prior ineffective systemic therapies.

The results suggest IL-17A inhibitors could be a promising treatment for pediatric Darier disease.

Abstract

Darier disease is a genodermatosis that significantly affects patients’ quality of life. We present the case of a 16-year-old patient whose quality of life remained markedly impaired despite systemic treatment. The patient experienced substantial clinical improvement in cutaneous lesions and quality of life following treatment with an interleukin (IL)-17A inhibitor. IL-17A inhibitors have demonstrated benefit in adults with Darier disease. In this case, we also observed therapeutic efficacy in a pediatric patient, supporting the relevance of this treatment approach in younger individuals. IL-17A inhibitors may play an important role in the management of Darier disease and represent a promising therapeutic option for pediatric patients, particularly in cases refractory to conventional therapies.

Figures